Karim Benali, Laurent Macle, Michel Haïssaguerre, Kinan Kneizeh, Konstantinos Vlachos, Maasaki Yokoyamah, Cinzia Monaco, Ruxandra Sava, Antoine Da Costa, Jason G Andrade
{"title":"Catheter ablation of paroxysmal atrial fibrillation and disease progression: Magnitude of the antiprogression effect and role of intervention timing.","authors":"Karim Benali, Laurent Macle, Michel Haïssaguerre, Kinan Kneizeh, Konstantinos Vlachos, Maasaki Yokoyamah, Cinzia Monaco, Ruxandra Sava, Antoine Da Costa, Jason G Andrade","doi":"10.1016/j.hrthm.2024.12.026","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Recent randomized controlled trials (RCTs) have shown that catheter ablation of paroxysmal atrial fibrillation (AF) is associated with a lower incidence of progression to persistent AF compared with the use of antiarrhythmic drug (AAD) therapy.</p><p><strong>Objective: </strong>This meta-analysis aimed to investigate the magnitude of the antiprogression effect of catheter ablation as well as the effect of intervention timing.</p><p><strong>Methods: </strong>MEDLINE/EMBASE databases were searched until April 1, 2024 for RCTs comparing catheter ablation and AAD therapy for the treatment of paroxysmal AF and reporting the rate of progression to persistent AF at 3 years (PROSPERO CRD42024534288).</p><p><strong>Results: </strong>A total of 1287 references were retrieved, of which 5 RCTs met inclusion criteria. The rate of progression to persistent AF was 8.3% (95% confidence interval [CI] 5.4-11.2, I<sup>2</sup> = 67.2%) at 3 years. The 3-year rate of progression to persistent AF was significantly lower in patients randomized to catheter ablation (1.8%; 95% CI 0.3-3.3; I<sup>2</sup> = 0%) compared with AAD (14.9%; 95% CI 9.3-20.5; I<sup>2</sup> = 71.9%); representing a risk ratio of progression to persistent AF at 3 years of 0.15 (95% CI 0.08-0.28; I<sup>2</sup> = 0%; P < .001) for catheter ablation vs AAD therapy. Catheter ablation appeared similarly efficient in reducing progression of AF when used as first-line or non-first-line therapy (risk ratio [RR] = 0.19; 95% CI 0.07-0.48 and RR = 0.13, 95% CI 0.05-0.29, respectively, P<sub>interaction</sub> = .551).</p><p><strong>Conclusion: </strong>The risk of progression to persistent AF at 3 years appears to be reduced by almost 7-fold in patients with paroxysmal AF treated using catheter ablation compared with patients treated using AAD therapy, regardless of the timing of the intervention.</p>","PeriodicalId":12886,"journal":{"name":"Heart rhythm","volume":" ","pages":""},"PeriodicalIF":5.6000,"publicationDate":"2024-12-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Heart rhythm","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.hrthm.2024.12.026","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
引用次数: 0
Abstract
Background: Recent randomized controlled trials (RCTs) have shown that catheter ablation of paroxysmal atrial fibrillation (AF) is associated with a lower incidence of progression to persistent AF compared with the use of antiarrhythmic drug (AAD) therapy.
Objective: This meta-analysis aimed to investigate the magnitude of the antiprogression effect of catheter ablation as well as the effect of intervention timing.
Methods: MEDLINE/EMBASE databases were searched until April 1, 2024 for RCTs comparing catheter ablation and AAD therapy for the treatment of paroxysmal AF and reporting the rate of progression to persistent AF at 3 years (PROSPERO CRD42024534288).
Results: A total of 1287 references were retrieved, of which 5 RCTs met inclusion criteria. The rate of progression to persistent AF was 8.3% (95% confidence interval [CI] 5.4-11.2, I2 = 67.2%) at 3 years. The 3-year rate of progression to persistent AF was significantly lower in patients randomized to catheter ablation (1.8%; 95% CI 0.3-3.3; I2 = 0%) compared with AAD (14.9%; 95% CI 9.3-20.5; I2 = 71.9%); representing a risk ratio of progression to persistent AF at 3 years of 0.15 (95% CI 0.08-0.28; I2 = 0%; P < .001) for catheter ablation vs AAD therapy. Catheter ablation appeared similarly efficient in reducing progression of AF when used as first-line or non-first-line therapy (risk ratio [RR] = 0.19; 95% CI 0.07-0.48 and RR = 0.13, 95% CI 0.05-0.29, respectively, Pinteraction = .551).
Conclusion: The risk of progression to persistent AF at 3 years appears to be reduced by almost 7-fold in patients with paroxysmal AF treated using catheter ablation compared with patients treated using AAD therapy, regardless of the timing of the intervention.
期刊介绍:
HeartRhythm, the official Journal of the Heart Rhythm Society and the Cardiac Electrophysiology Society, is a unique journal for fundamental discovery and clinical applicability.
HeartRhythm integrates the entire cardiac electrophysiology (EP) community from basic and clinical academic researchers, private practitioners, engineers, allied professionals, industry, and trainees, all of whom are vital and interdependent members of our EP community.
The Heart Rhythm Society is the international leader in science, education, and advocacy for cardiac arrhythmia professionals and patients, and the primary information resource on heart rhythm disorders. Its mission is to improve the care of patients by promoting research, education, and optimal health care policies and standards.